You are here: Industry Insights > Farxiga

News List

FDA approves AstraZeneca’s Farxiga for chronic kidney disease treatment pharmaceutical-technology
May 06, 2021
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Farxiga (dapagliflozin) for treating chronic kidney disease (CKD) in patients who are at the risk of progression with and without type-2 diabetes.
Update on the DARE-19 Phase III Trial for Farxiga in COVID-19 americanpharmaceuticalreview
April 13, 2021
AstraZeneca and Saint Luke’s Mid America Heart Institute announced high-level results of the primary analysis from the DARE-19 Phase III trial assessing the potential of Farxiga (dapagliflozin) to treat patients hospitalized with COVID-19 who are at ...
Farxiga Granted Priority Review in US for Chronic Kidney Disease americanpharmaceuticalreview
January 14, 2021
AstraZeneca’s Farxiga (dapagliflozin) has been granted Priority Review in the US for the treatment of new or worsening chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D).
AstraZeneca's Farxiga cuts kidney disease risks by 39% in trial that could 'rewrite' the treatment textbook fiercepharma
September 01, 2020
AstraZeneca set the tone for the future of SGLT2 diabetes medicines in May with Farxiga's heart-helping FDA approval in patients with or without diabetes.
AZ' Farxiga hits all goals in chronic kidney disease trial pharmatimes
July 29, 2020
AstraZeneca's Farxiga’s (dapagliflozin) has hit all primary and secondary endpoints in a late stage trial assessing its use in patients with chronic kidney disease (CKD).
Farxiga Granted Fast Track Designation for Heart Failure Following Acute Myocardial Infarction americanpharmaceuticalreview
July 24, 2020
AstraZeneca has been granted Fast Track Designation in the US for the development of Farxiga (dapagliflozin) to reduce the risk of hospitalization for heart failure (hHF) or cardiovascular (CV) death in adults following an acute myocardial infarction ...
AZ' Farxiga fast-tracked for heart failure following MI pharmatimes
July 20, 2020
AstraZeneca's Farxiga (dapagliflozin) has been granted a Fast Track Designation in the US for reducing the risk of hospitalisation for heart failure (hHF) or cardiovascular (CV) death in adults following an acute myocardial infarction (MI) or heart attack
FDA Approves New Treatment for Heart Failure with Reduced Ejection Fraction americanpharmaceuticalreview
May 08, 2020
The U.S. Food and Drug Administration (FDA) approved Farxiga (dapagliflozin) oral tablets for adults with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure.
FDA approves Farxiga for heart failure expresspharma
May 06, 2020
Farxiga was shown in a clinical trial to improve survival and reduce the need for hospitalisation in adults with heart failure with reduced ejection fraction.
AstraZeneca and Saint Luke’s Mid America Heart Institute initiate Phase III DARE-19 trial with Farxiga in COVID-19 patients worldpharmanews
April 26, 2020
AstraZeneca and Saint Luke's Mid America Heart Institute have initiated a randomised, global Phase III trial to assess the potential of Farxiga (dapagliflozin).

Previous page 1 2 3 Next page